Douglas A. Dachille

Douglas A. Dachille is a declared insider at 4 companies (senior executive); the most frequent names are BridgeBio Pharma, Inc., Equitable Holdings, Inc. and American International Group, Inc. We count 8 filings; the first trade dates from 2 June 2021 and the latest from 22 June 2026.

Both buying and selling appear: 3 purchases worth €169k, against 1 sale worth €859k. Netting one side against the other leaves €691k of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 4 share grants.

In size, the median ticket on the buying side is €74k. Clusters matter here: 1 out of 3 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.

Most recently, on 24 June 2026, the filings show a share grant in BridgeBio Pharma, Inc. The last purchase on record was published on 5 February 2025, which is 620 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.